Successful and well-tolerated second line therapy with Cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer

Journal of Gastrointestinal Cancer

Volumn 39, Issue 1-4, 2008, Pages 26-28

  Geurs, F ^a   Vandewaeter, S ^a   Ponette, S ^a   Ponette, J ^a   Knape, S ^a   Demetter, P ^b  

^a RZ Sint Maria ^*  (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; GAMMA GLUTAMYLTRANSFERASE; IRINOTECAN; OXALIPLATIN; RALTITREXED; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

AGED; ARTICLE; ASCITES; CASE REPORT; CLINICAL FEATURE; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; HEMATOCHEZIA; HUMAN; JAUNDICE; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PORTAL HYPERTENSION; PRIORITY JOURNAL; WEIGHT REDUCTION; COLON TUMOR; LIVER DISEASE; LIVER TUMOR; METASTASIS; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALE; QUINAZOLINES; THIOPHENES;

EID: 69849083270     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-009-9060-4     Document Type: Article

References (16)

1. JH Doroshow TW Synold D Gandara, et al. 2003 Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group Semin Oncol 30 14 19 10.1016/S0093-7754(03)00400-7 14523790 10.1016/S0093-7754(03)00400-7 1:CAS:528:DC%2BD3sXovFGks7g%3D
2. TW Synold CH Takimoto JH Doroshow, et al. 2007 Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic dysfunction, a National Cancer Institute Organ Dysfunction Working Group Study Clin Cancer Res 15 13 3660 3666 doi:10.1158/1078-0432.CCR-06-2385 10.1158/1078-0432.CCR-06-2385 (Pubitemid 46955130)
3. C Twelves R Glynne-Jones J Cassidy, et al. 1999 Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites Clin Cancer Res 5 1696 1702 10430071 1:CAS:528: DyaK1MXltVCqtrw%3D
4. N Moosmann D Laessig JH Michaely C Schulz V Heinemann 2007 Effective second-line treatment with cetuximab bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia Onkologie 30 509 512 10.1159/000106098 17890890 10.1159/000106098 (Pubitemid 47462061)
5. P Rougier E Van Cutsem E Bajetta, et al. 1998 Randomnised trail of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer The Lancet 352 1407 1412 10.1016/S0140-6736(98)03085-2 10.1016/S0140-6736(98)03085-2 1:CAS:528: DyaK1cXnsVSmsLo%3D (Pubitemid 28510873)
6. D Cunningham S Pyrhonen RD James, et al. 1998 Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastastic colorectal cancer Lancet 352 1413 1418 10.1016/S0140-6736(98)02309-5 9807987 10.1016/S0140-6736(98)02309-5 1:CAS:528:DyaK1cXnsVSmsLs%3D (Pubitemid 28510874)
7. MT Seymour TSN Maughan JA Ledermann, et al. 2007 Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS) a randomised controlled trial Lancet 370 143 152 doi:10.1016/S0140-6736(07)61087-3 17630037 10.1016/S0140-6736(07)61087-3 1:CAS:528:DC%2BD2sXns12jtLs%3D (Pubitemid 47042894)
8. E Raymond V Boige S Faivre, et al. 2002 Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction J. Clin Oncol 20 4303 4312 10.1200/JCO.2002.03.123 12409328 10.1200/JCO.2002.03.123 1:CAS:528:DC%2BD38Xpt1CjtLg%3D (Pubitemid 35266290)
9. AP Venook KC Enders G Fleming, et al. 2003 A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation. CALG 9863 Ann Oncol 14 1783 1790 10.1093/annonc/mdg493 14630685 10.1093/annonc/mdg493 1:STN:280:DC%2BD3srltVWnsw%3D%3D (Pubitemid 38029051)
10. C Shousong F Durrani Y Rustum 2005 Synergistic antitumor activity of capecitabin in combination with irinotecan Clin Colorectal Ca 4 336 343 10.3816/CCC.2005.n.007
11. JP Stevenson M Relinger LAJ Kluijtmans, et al. 2001 Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer J Clin Onc 19 4081 4087 1:CAS:528:DC%2BD3MXotVakt7Y%3D
12. E Van Cutsem 2002 Raltitrexed: current status and future Ann Oncol 13 513 522 10.1093/annonc/mdf054 12056700 10.1093/annonc/mdf054 (Pubitemid 34461133)
13. F Geurs S Ponette J Ponette, et al. 2006 Fixed low dose irinotecan and raltitrex provide TTP comparable to other regimens, in oxaliplatin refractory colorectal cancer patients Crit Rev Oncol Hematol 60S1 S19 S20
14. D Cunningham Y Humblet S Siena, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer NEJM 351 337 345 10.1056/NEJMoa033025 15269313 10.1056/NEJMoa033025 1:CAS:528:DC%2BD2cXlvFGitbk%3D (Pubitemid 38944402)
15. A Sobrero J Maurel L Fehrenbacher, et al. 2008 EPIC: phase III trial of cetuximab plus irinotecan after fluorpyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 14 2311 2319 18390971 10.1200/JCO.2007.13.1193 1:CAS:528:DC%2BD1cXntVOltrk%3D
16. Nolting A, Fox FE, Kovar A. Clinical drug development of cetuximab, a monoclonal antibody. In: Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development. Weinheim: Wiley-VCH; 2006.